Voyager Pharmaceutical Completes Alzheimer's Study

Voyager Pharmaceutical Corp. announced the completion of its 48-week Phase II Alzheimer's disease study -- a major clinical achievement for the biopharmaceutical company focused on diseases of aging and development.

Yahoo News (http://biz.yahoo.com/prnews/050216/clw039_1.html)